Patents by Inventor Batu ERMAN

Batu ERMAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NATURAL KILLER (NK) CELLS EXPRESSING AN ANTIGEN-SPECIFIC FUNCTIONAL T CELL RECEPTOR (TCR) COMPLEX, METHODS FOR PRODUCTION THEREOF, AND METHODS FOR THERAPEUTIC USE THEREOF
    Publication number: 20240100095
    Abstract: The invention provides modified Natural Killer (NK) cells expressing an antigen-specific functional T cell receptor (TCR) complex. These NK cells are used for T cell receptor (TCR) gene therapy in order to circumvent any risk of mispairing of the TCR ? and ? chains and to provide Major Histocompatibility Complex (MHC)-restricted antigen-specific cytotoxicity to the NK cells. The invention additionally provides methods for producing the modified NK cells, therapeutic compositions including the modified NK cells, and methods for using the modified NK cells in therapy of cancer, viral infections, autoimmunity, and graft versus host disease (GvHD).
    Type: Application
    Filed: September 11, 2023
    Publication date: March 28, 2024
    Applicants: NOVA SOUTHEASTERN UNIVERSITY, SABANCI ÜNIVERSITESI
    Inventors: Tolga SUTLU, Adil Doganay DURU, Batu ERMAN
  • DNA polymerase gamma inhibitor and uses thereof
    Patent number: 11883419
    Abstract: Pol ? protein inhibitor compounds are useful for selectively inhibiting the growth of MLH1 mutant/deficient tumor or cancer cells due to a synthetic lethal relationship between MLH1 and Pol ?. The compounds were shown to directly interact with Pol ? and inhibit its biological function and cause cancer cell death and an inhibition of tumor or cancer cell growth in multiple assays.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: January 30, 2024
    Assignees: ACIBADEM MEHMET ALI AYDINLAR UNIVERSITESI, SABANCI UNIVERSITESI, KOC UNIVERSITESI
    Inventors: Meltem Muftuoglu, Batu Erman, Burak Erman
  • Natural killer (NK) cells expressing an antigen-specific functional T cell receptor (TCR) complex, methods for production thereof, and methods for therapeutic use thereof
    Patent number: 11752172
    Abstract: The invention provides modified Natural Killer (NK) cells expressing an antigen-specific functional T cell receptor (TCR) complex. These NK cells are used for T cell receptor (TCR) gene therapy in order to circumvent any risk of mispairing of the TCR a and ? chains and to provide Major Histocompatibility Complex (MHC)-restricted antigen-specific cytotoxicity to the NK cells. The invention additionally provides methods for producing the modified NK cells, therapeutic compositions including the modified NK cells, and methods for using the modified NK cells in therapy of cancer, viral infections, autoimmunity, and graft versus host disease (GvHD).
    Type: Grant
    Filed: January 4, 2018
    Date of Patent: September 12, 2023
    Assignees: NOVA SOUTHEASTERN UNIVERSITY, SABANCI ÜNIVERSITESI
    Inventors: Tolga Sutlu, Adil Doganay Duru, Batu Erman
  • NOVEL DNA POLYMERASE GAMMA INHIBITOR AND USES THEREOF
    Publication number: 20210275548
    Abstract: Pol ? protein inhibitor compounds are useful for selectively inhibiting the growth of MLH1 mutant/deficient tumor or cancer cells due to a synthetic lethal relationship between MLH1 and Pol ?. The compounds were shown to directly interact with Pol ? and inhibit its biological function and cause cancer cell death and an inhibition of tumor or cancer cell growth in multiple assays.
    Type: Application
    Filed: June 25, 2018
    Publication date: September 9, 2021
    Applicants: ACIBADEM MEHMET ALI AYDINLAR UNIVERSITESI, SABANCI UNIVERSITESI, KOC UNIVERSITESI
    Inventors: Meltem MUFTUOGLU, Batu ERMAN, Burak ERMAN
  • NATURAL KILLER (NK) CELLS EXPRESSING AN ANTIGEN-SPECIFIC FUNCTIONAL T CELL RECEPTOR (TCR) COMPLEX, METHODS FOR PRODUCTION THEREOF, AND METHODS FOR THERAPEUTIC USE THEREOF
    Publication number: 20190365812
    Abstract: The invention provides modified Natural Killer (NK) cells expressing an antigen-specific functional T cell receptor (TCR) complex. These NK cells are used for T cell receptor (TCR) gene therapy in order to circumvent any risk of mispairing of the TCR a and ? chains and to provide Major Histocompatibility Complex (MHC)-restricted antigen-specific cytotoxicity to the NK cells. The invention additionally provides methods for producing the modified NK cells, therapeutic compositions including the modified NK cells, and methods for using the modified NK cells in therapy of cancer, viral infections, autoimmunity, and graft versus host disease (GvHD).
    Type: Application
    Filed: January 4, 2018
    Publication date: December 5, 2019
    Applicants: NOVA SOUTHEASTERN UNIVERSITY, SABANCI ÜNIVERSITESI
    Inventors: Tolga SUTLU, Adil Doganay DURU, Batu ERMAN